Open AccessRandomized Controlled Trial of Rituximab in Patients With Graves' Orbitopathy
Author(s) -
Marius N. Stan,
James A. Garrity,
Barbara Gisella Carranza Leon,
Thapa Prabin,
Elizabeth A. Bradley,
Rebecca S. Bahn
Publication year - 2014
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2014-2572
Subject(s) - medicine , clinical endpoint , placebo , rituximab , adverse effect , randomized controlled trial , diplopia , surgery , alternative medicine , pathology , lymphoma
Graves' orbitopathy (GO) is a potentially sight-threatening disease for which available medical therapy is not uniformly successful. Multiple case series suggest that rituximab (RTX) may be effective therapy for GO patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom